Short Interest in Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Drops By 47.5%

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 501,100 shares, a drop of 47.5% from the November 15th total of 953,700 shares. Based on an average daily trading volume, of 1,100 shares, the days-to-cover ratio is presently 455.5 days.

Wall Street Analyst Weigh In

Several research firms have commented on RCDTF. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th. Barclays upgraded Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd.

Recordati Industria Chimica e Farmaceutica Stock Down 1.2 %

Shares of OTCMKTS:RCDTF traded down $0.64 during midday trading on Friday, reaching $51.61. 1 shares of the company’s stock were exchanged, compared to its average volume of 239. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95. The company’s 50 day simple moving average is $52.21 and its two-hundred day simple moving average is $52.02. Recordati Industria Chimica e Farmaceutica has a 12 month low of $52.25 and a 12 month high of $52.25.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.